<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34773664</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-3350</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>75</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The pathophysiology of Wilson's disease visualized: A human <sup>64</sup> Cu PET study.</ArticleTitle>
        <Pagination>
          <StartPage>1461</StartPage>
          <EndPage>1470</EndPage>
          <MedlinePgn>1461-1470</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.32238</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Wilson's disease (WD) is a genetic disease with systemic accumulation of copper that leads to symptoms from the liver and brain. However, the underlying defects in copper transport kinetics are only partly understood. We sought to quantify hepatic copper turnover in patients with WD compared with heterozygote and control subjects using PET with copper-64 (<sup>64</sup> Cu) as a tracer. Furthermore, we assessed the diagnostic potential of the method.</AbstractText>
          <AbstractText Label="APPROACH AND RESULTS" NlmCategory="RESULTS">Nine patients with WD, 5 healthy heterozygote subjects, and 8 healthy controls were injected with an i.v. bolus of <sup>64</sup> Cu followed by a 90-min dynamic PET scan of the liver and static whole-body PET/CT scans after 1.5, 6, and 20 h. Blood <sup>64</sup> Cu concentrations were measured in parallel. Hepatic copper retention and redistribution were evaluated by standardized uptake values (SUVs). At 90 min, hepatic SUVs were similar in the three groups. In contrast, at 20 h postinjection, the SUV in WD patients (mean ± SEM, 31 ± 4) was higher than in heterozygotes (24 ± 3) and controls (21 ± 4; p &lt; 0.001). An SUV-ratio of hepatic <sup>64</sup> Cu concentration at 20 and 1.5 h completely discriminated between WD patients and control groups (p &lt; 0.0001; ANOVA). By Patlak analysis of the initial 90 min of the PET scan, the steady-state hepatic clearance of <sup>64</sup> Cu was estimated to be slightly lower in patients with WD than in controls (p = 0.04).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS"><sup>64</sup> Cu PET imaging enables visualization and quantification of the hepatic copper retention characteristic for WD patients. This method represents a valuable tool for future studies of WD pathophysiology, and may assist the development of therapies, and accurate diagnosis.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sandahl</LastName>
            <ForeName>Thomas Damgaard</ForeName>
            <Initials>TD</Initials>
            <Identifier Source="ORCID">0000-0001-9807-6852</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gormsen</LastName>
            <ForeName>Lars C</ForeName>
            <Initials>LC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kjaergaard</LastName>
            <ForeName>Kristoffer</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vendelbo</LastName>
            <ForeName>Mikkel Holm</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munk</LastName>
            <ForeName>Ditte Emilie</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munk</LastName>
            <ForeName>Ole Lajord</ForeName>
            <Initials>OL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bender</LastName>
            <ForeName>Dirk</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keiding</LastName>
            <ForeName>Susanne</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vase</LastName>
            <ForeName>Karina H</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frisch</LastName>
            <ForeName>Kim</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vilstrup</LastName>
            <ForeName>Hendrik</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ott</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006527" MajorTopicYN="Y">Hepatolenticular Degeneration</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34773664</ArticleId>
        <ArticleId IdType="doi">10.1002/hep.32238</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Scheinberg IH, Sternlieb I. Wilson’s disease. Philadelphia, PA: WB Saunders; 1984.</Citation>
        </Reference>
        <Reference>
          <Citation>Gitlin JD. Wilson disease. Gastroenterology. 2003;125:1868-77.</Citation>
        </Reference>
        <Reference>
          <Citation>Lutsenko S, Petris MJ. Function and regulation of the mammalian copper-transporting ATPases: insights from biochemical and cell biological approaches. J Membr Biol. 2003;191:1-12.</Citation>
        </Reference>
        <Reference>
          <Citation>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56:671-85.</Citation>
        </Reference>
        <Reference>
          <Citation>Roberts EA, Schilsky ML; American Association for the Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089-111.</Citation>
        </Reference>
        <Reference>
          <Citation>Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nat Rev Dis Primers. 2018;4:21.</Citation>
        </Reference>
        <Reference>
          <Citation>Tang N, Sandahl TD, Ott P, Kepp KP. Computing the pathogenicity of Wilson’s disease ATP7B mutations: implications for disease prevalence. J Chem Inf Model. 2019;59:5230-43.</Citation>
        </Reference>
        <Reference>
          <Citation>Stattermayer AF, Entenmann A, Gschwantler M, Zoller H, Hofer H, Ferenci P. The dilemma to diagnose Wilson disease by genetic testing alone. Eur J Clin Invest. 2019;49:e13147.</Citation>
        </Reference>
        <Reference>
          <Citation>Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The prevalence of Wilson’s disease: an update. Hepatology. 2020;71:722-32.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferenci P, Stremmel W, Członkowska A, Szalay F, Viveiros A, Stättermayer AF, et al. Age and sex but not ATP7B genotype effectively influence the clinical phenotype of Wilson disease. Hepatology. 2019;69:1464-76.</Citation>
        </Reference>
        <Reference>
          <Citation>Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RD. Treatment of Wilson’s disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci. 1986;292:344-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Osborn SB, Roberts CN, Walshe JM. Uptake of radiocopper by the liver. A study of patients with Wilson’s disease and various control groups. Clin Sci. 1963;24:13-22.</Citation>
        </Reference>
        <Reference>
          <Citation>Biesold D, Günther K. Improved method for investigation of copper metabolism in patients with Wilson’s disease using 64Cu. Clin Chim Acta. 1972;42:353-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Czlonkowska A, Galewicz A, Rodo M, Wehr H. Observations on copper metabolism in Wilson’s disease. Acta Univ Carol Med Monogr. 1973;56:175-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Czlonkowska A, Rodo M, Wierzchowska-Ciok A, Smolinski L, Litwin T. Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver Int. 2018;38:1860-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Kjaergaard K, Sandahl TD, Frisch K, Vase KH, Keiding S, Vilstrup H, et al. Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [(64)Cu]copper PET/CT. EJNMMI Radiopharm Chem. 2020;5:15.</Citation>
        </Reference>
        <Reference>
          <Citation>Avila-Rodriguez MA, Rios C, Carrasco-Hernandez J, Manrique-Arias JC, Martinez-Hernandez R, García-Pérez FO, et al. Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers. EJNMMI Res. 2017;7:98.</Citation>
        </Reference>
        <Reference>
          <Citation>Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, et al. Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015;29:482-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Piccardo A, Paparo F, Puntoni M, Righi S, Bottoni G, Bacigalupo L, et al. (64)CuCl2 PET/CT in prostate cancer relapse. J Nucl Med. 2018;59:444-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Panichelli P, Villano C, Cistaro A, Bruno A, Barbato F, Piccardo A, et al. Imaging of brain tumors with copper-64 chloride: early experience and results. Cancer Biother Radiopharm. 2016;31:159-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Wachsmann J, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol. 2016;22:221-31.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang F, Jiao P, Qi M, Frezza M, Dou QP, Yan B. Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry. Curr Med Chem. 2010;17:2685-98.</Citation>
        </Reference>
        <Reference>
          <Citation>Peng F, Lutsenko S, Sun X, Muzik O. Imaging copper metabolism imbalance in Atp7b (-/-) knockout mouse model of Wilson’s disease with PET-CT and orally administered 64CuCl2. Mol Imaging Biol. 2012;14:600-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Peng F, Lutsenko S, Sun X, Muzik O. Positron emission tomography of copper metabolism in the Atp7b-/- knock-out mouse model of Wilson’s disease. Mol Imaging Biol. 2012;14:70-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23:139-42.</Citation>
        </Reference>
        <Reference>
          <Citation>Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 2005;11:441-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5:584-90.</Citation>
        </Reference>
        <Reference>
          <Citation>Kjaergaard K, Frisch K, Sørensen M, Munk OL, Hofmann AF, Horsager J, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis. J Hepatol. 2021;74:58-65.</Citation>
        </Reference>
        <Reference>
          <Citation>Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38:717-27.</Citation>
        </Reference>
        <Reference>
          <Citation>Osborn SB, Walshe JM. Studies with radiocopper (64Cu) in Wilson’s disease: dynamics of copper transport. Clin Sci. 1965;29:575-81.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
